Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/212324
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and/or bloodstream infection produced by gram-positive cocci |
Autor: | Hidalgo-Tenorio, Carmen; Vinuesa García, David; Plata-Ciezar, Antonio; Martín-Dávila, Pilar; Iftimie, Simona; Sequera, Sergio; Loeches, Belén; López-Cortés, Luis Eduardo; Fariñas, María del Carmen; Fernández-Roldán, Concepción; Javier-Martinez, Rosario; Muñoz García, Patricia; Arenas-Miras, Maria del Mar; Martínez-Marcos, Francisco Javier; Miró, José María; Herrero-Rodríguez, Carmen; Bereciartúa, Elena; De Jesus, Samantha E.; Pasquau-Liaño, Juan | Palabras clave: | Endocarditis Bloodstream infections Dalbavancin |
Fecha de publicación: | 2019 | Editor: | BioMed Central | Citación: | Annals of Clinical Microbiology and Antimicrobials 18: 30 (2019) | Resumen: | [Objectives] To analyse the effectiveness of dalbavancin (DBV) in clinical practice as consolidation therapy in patients with bloodstream infection (BSI) and/or infective endocarditis (IE) produced by gram-positive cocci (GPC), as well as its safety and pharmacoeconomic impact. [Methods] A multicentre, observational and retrospective study was conducted of hospitalised patients with IE and/or BSI produced by GPC who received at least one dose of DBV. Clinical response was assessed during hospitalization, at 3 months and at 1 year. [Results] Eighty-three patients with median age of 73 years were enrolled; 73.5% were male; 59.04% had BSI and 49.04% IE (44.04% prosthetic valve IE, 32.4% native IE, 23.5% pacemaker lead). The most frequently isolated microorganism was Staphylococcus aureus in BSI (49%) and coagulase-negative staphylococci in IE (44.1%). All patients with IE were clinically cured in hospital; at 12 months, there was 2.9% loss to follow-up, 8.8% mortality unrelated to IE, and 2.9% therapeutic failure rate. The percentage effectiveness of DBV to treat IE was 96.7%. The clinical cure rate for BSI was 100% during hospital stay and at 3 months; there were no recurrences or deaths during the follow-up. No patient discontinued treatment for adverse events. The saving in hospital stay was 636 days for BSI (315,424.20€) and 557 days for IE (283,187.45€). [Conclusions] DBV is an effective consolidation antibiotic therapy in clinically stabilized patients with IE and/or BSI. It proved to be a cost-effective treatment, reducing the hospital stay, thanks to the pharmacokinetic/pharmacodynamic profile of this drug. | Versión del editor: | https://doi.org/10.1186/s12941-019-0329-6 | URI: | http://hdl.handle.net/10261/212324 | DOI: | 10.1186/s12941-019-0329-6 | Identificadores: | doi: 10.1186/s12941-019-0329-6 e-issn: 1476-0711 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
dalbacencocci.pdf | 909,92 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
PubMed Central
Citations
40
checked on 15-abr-2024
SCOPUSTM
Citations
72
checked on 07-may-2024
WEB OF SCIENCETM
Citations
59
checked on 29-feb-2024
Page view(s)
147
checked on 07-may-2024
Download(s)
110
checked on 07-may-2024